35
Participants
Start Date
June 30, 2012
Primary Completion Date
May 31, 2016
Study Completion Date
August 31, 2017
DC Vaccine + IFN
"Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.~IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks."
AdVTMM2/DC Vaccination
Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
University of Pittsburgh Cancer Institute, Pittsburgh
National Cancer Institute (NCI)
NIH
Lisa H. Butterfield, Ph.D.
OTHER